Sarah Potter

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

K. C. Morris, Mohammed Salah Ibrahim, K. Y. Wong, 2022, medRxiv.

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Patricia A. H. Williams, Steve B Jones, K. Y. Wong, 2021, The Lancet.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Steve B Jones, K. Y. Wong, Chamil H. Hettiarachchi, 2021, Lancet.

Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome

L. Abbeduto, F. Tassone, R. Hagerman, 2020, Journal of Neurodevelopmental Disorders.

Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT.

C. Gamble, R. Appleton, K. Woolfall, 2020, Health technology assessment.

A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours.

S. Halford, G. Holder, U. Banerji, 2017 .

Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial

C. Gamble, C. Bevan, J. Small, 2019, The Lancet.

Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial

C. Gamble, C. Bevan, J. Small, 2019, The Lancet.